In addition, although more and more studies have shown that elevated levels of Lp-PLA2 is a high-risk underlying factor for cardiovascular diseases, an authoritative randomized controlled clinical trial study shows that in patients with stable coronary heart disease, the Lp-PLA2 inhibitor darapladib did not significantly reduce the probability of cardiovascular death, myocardial infarction or stroke in such patients (White et al., 2014). Here, PLA2G7 is linked to coronary artery disorder.